DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market Program on Nasdaq
DBV Technologies Announces the Filing of its 2026 Half-Year Report - Conditions for Accessing or Consulting the Report
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
